Vietnam’s pharmaceutical industry is entering a historic turning point, transitioning a fragmented, small-scale generic drug manufacturing base into a modern production ecosystem aligned with international standards and deeply integrated into the global supply chain. This transformation is not only the result of internal efforts by enterprises but also an inevitable outcome of fundamental changes in the regulatory framework, foreign direct investment (FDI) flows, and increasingly stringent treatment quality requirements in the context of rapid population aging.
From the perspective of an experienced market researcher, analyzing the current state of production and forecasting factory operation trends toward 2030 requires a multidimensional approach, combining macroeconomic indicators, policy drivers, and structural changes in corporate governance among leading enterprises.
Market Overview and Macroeconomic Growth Drivers
Vietnam’s pharmaceutical market has experienced remarkable growth over the past decade. The market size has increased USD 3.4 billion in 2015 to nearly USD 7 billion in 2023. According to economic outlook reports, the market is expected to reach USD 10 billion by 2026 and continue expanding strongly during 2027–2030.
This growth is supported by four key pillars: stable economic growth, rapid increases in per capita income, rising health awareness, and irreversible demographic trends.
Economically, Vietnam maintains a GDP growth target of 6.5–7% for 2024–2025 and is expected to sustain a new growth cycle through 2030. Per capita income is projected to rise USD 4,300 in 2023 to USD 4,900 by 2025, enabling higher spending on quality healthcare services. At the same time, total healthcare expenditure is expected to increase USD 24.7 billion in 2024 to USD 57.1 billion by 2029.
Demographically, Vietnam is one of the fastest-aging populations in the world. In 2023, people aged 60 and above aced for 13.9% of the population, and this figure is projected to exceed 25% by 2050. Vietnam is expected to officially enter an aging society by 2036, creating both pressure on the healthcare system and significant opportunities for pharmaceutical manufacturers focusing on chronic disease treatments.
.png)
Policy Framework and National Strategy
The development of the pharmaceutical industry is closely tied to government direction. National strategies aim to position Vietnam’s pharmaceutical sector among the top three in ASEAN by 2030.
The core objective is to achieve self-sufficiency in domestic drug supply, targeting 80% of volume and 70% of market value by 2030. To achieve this, the government has introduced a range of incentives, including administrative reforms and financial support for innovative drugs, vaccines, and biologics.
The 2023 Bidding Law, effective January 1, 2024, provides strong support for domestic manufacturers by prioritizing locally produced drugs in hospital procurement when technical and quality requirements are met.
Manufacturing Standards Upgrade: EU-GMP and Beyond
WHO-GMP is now considered the minimum requirement. Leading companies are actively investing in EU-GMP, Japan-GMP, and PIC/S-GMP facilities to compete in high-value segments and export markets.
.png)
Although these standards require substantial investment, they offer advantages in hospital tenders and positioning in premium segments.
Digital Transformation and Smart Factories
By 2030, operational efficiency will depend heavily on digital transformation. Technologies such as ERP, MES, and LIMS are becoming standard systems.
AI and IoT are increasingly used in research, environmental monitoring, and supply chain management, enhancing efficiency and ensuring compliance with international GMP requirements.
Specialized Pharmaceutical Industrial Zones
A major trend is the development of specialized pharmaceutical industrial zones, enabling shared infrastructure, optimized waste treatment, and stronger FDI attraction.
The Thai Binh Pharmaceutical-Biotech Industrial Zone is a leading example, aiming to become a regional production hub.
API Self-Sufficiency and Supply Chain Risks
Currently, Vietnam imports approximately 90% of pharmaceutical raw materials. The national strategy aims to achieve 20–30% domestic API production by 2030.
Biopharmaceutical APIs are seen as a breakthrough direction.
M&A and FDI Impact
M&A activities are reshaping the industry. Partnerships with multinational corporations bring advanced technology, global governance standards, and R&D capabilities.
ESG and Green Manufacturing
By 2030, ESG compliance will become mandatory for accessing international markets. Companies must reduce emissions, manage waste, and optimize resource usage.
Human Resource Challenges
A shortage of highly skilled personnel remains a major bottleneck, particularly in QA, QC, validation, and automation engineering.
Economic Outlook and Investment Efficiency
Investing in high-standard manufacturing is a long-term strategy. Despite high initial costs, companies with advanced facilities will achieve superior growth and profitability.
.png)
Conclusion and Strategic Recommendations
To succeed by 2030, companies must:
1. Commit to high-quality standards (EU-GMP)
2. Accelerate digital transformation
3. Invest in R&D and technology transfer
4. Strengthen supply chain resilience
5. Implement ESG practices
Vietnam has strong potential to become a leading pharmaceutical manufacturing hub in ASEAN.
